Lexicon Pharmaceuticals (LXRX) Posts Narrower than Expected Q2 Loss of 5c/Sh.
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $2.04 +0.99%
Revenue Growth %: -78.9%
Financial Fact:
Collaborative research: 27.69M
Today's EPS Names:
ALZN, ASPU, USAU, More
Revenue Growth %: -78.9%
Financial Fact:
Collaborative research: 27.69M
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
Lexicon Pharmaceuticals (NASDAQ: LXRX) reported Q2 EPS of ($0.05), $0.01 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $555 thousand versus the consensus estimate of $350 thousand.
For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.
For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald’s said to plan value strategy overhaul to revive US sales growth
- Shukran Coin in Nigeria Review – Here’s What You Need To Know in 2026
- Nucor projects Q3 2026 earnings above prior year, below estimates
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
